Ascend Recalls Metoprolol Succinate Tablets Due to Dissolution Failure
Ascend Laboratories recalls 9,216 bottles of Metoprolol Succinate Extended-Release Tablets (25 mg) due to failed dissolution specifications.
Use caution until it’s fixed
Failed Dissolution Specifications.
Contact the company
What happened, in plain English
Ascend Laboratories, LLC is recalling one lot of Metoprolol Succinate Extended-Release Tablets, USP, 25 mg because the product failed dissolution specifications. This means the tablets may not release the medication properly in the body, potentially affecting how well the drug works for patients taking it to treat heart conditions. The recall affects 9,216 bottles distributed nationwide. Read more at govinfonow.com/recall/35388-ascend-recalls-metoprolol-succinate-tablets-due-to-dissolution-failure.
Source Summary by GovInfoNow · govinfonow.com/recall/35388-ascend-recalls-metoprolol-succinate-tablets-due-to-dissolution-failure · Updated October 10, 2026 · FDA enforcement record: FDA #D-0393-2022
Cite this page
“Ascend Recalls Metoprolol Succinate Tablets Due to Dissolution Failure.” GovInfoNow, updated October 10, 2026. https://govinfonow.com/recall/35388-ascend-recalls-metoprolol-succinate-tablets-due-to-dissolution-failure. Based on FDA recall #D-0393-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0393-2022%22&limit=1).
Why it’s dangerous
The tablets failed dissolution specifications, which is a quality control test ensuring the drug releases at the correct rate. If the dissolution fails, the body might not absorb the full dose of Metoprolol Succinate needed to manage heart conditions effectively, leading to potential treatment failure.
Who’s affected
Patients who have been prescribed Metoprolol Succinate Extended-Release Tablets, USP, 25 mg by Ascend Laboratories and purchased them between the manufacturing date and March 2023. Individuals relying on this specific medication for heart health are most at risk of receiving a product that may not function as intended.
How to tell if you have this one
Check your bottle for NDC 67877-590-01 and Lot # 21143093 with an expiration date of March 2023. The label should state 'Manufactured by: Alkem Laboratories Ltd., Mumbai - 400 013, India' and 'Distributed by: Ascend Laboratories, LLC, Parsippany, NJ'.
- Brand
Ascend Laboratories- Category
Drug
What to do — step by step
Check your medication details
Verify if your bottle matches NDC 67877-590-01 and Lot # 21143093 with an expiration of March 2023.
Contact your pharmacist or doctor
Inform your healthcare provider about the recall to discuss alternative treatment options if you have this specific lot.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 17 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Ascend Laboratories recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0393-2022 (January 12, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0393-2022 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 10, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.